Trinity Biosystems raises $7.5M bridge to treat endocrine disorders
Trinity Biosystems, maker of a drug that can treat certain endocrine disorders, has brought in $7.5 million in bridge funding from Amgen Ventures, Life Science Partners, Lilly Ventures, Sanderling Ventures and SR One, according to Dow Jones VentureWire. Based in Menlo Park, Calif., the company has raised about $33.75 million since its first round of financing in 2004.
Next Story: Penguin Computing snaps up $1.5M for Linux cluster virtualization
Previous Story: Tethys picks up $25M for diabetes diagnostic
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.